Pembrolizumab-Induced Lichen Planus: A Rare Immune-Related Adverse Side Effect

Pembrolizumab is the first anti-programmed death protein-1 agent approved by the US Food and Drug Administration. It has demonstrated efficacy in melanoma, lung cancer, and other advanced solid tumours and hematologic malignancies. Various dermatological side effects including pruritus, maculopapula...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansal, Aditi, Singla, Ankur, Paul, Davinder, Kaur, Sukhjot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231724/
https://www.ncbi.nlm.nih.gov/pubmed/37266094
http://dx.doi.org/10.4103/idoj.idoj_377_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231724/
https://www.ncbi.nlm.nih.gov/pubmed/37266094
http://dx.doi.org/10.4103/idoj.idoj_377_22

Ejemplares similares